148 related articles for article (PubMed ID: 24972944)
1. Editorial comment.
Macchia RJ
Urology; 2014 Aug; 84(2):432. PubMed ID: 24972944
[No Abstract] [Full Text] [Related]
2. Re: Reasons for prescription change of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Kaplan SA
J Urol; 2015 Apr; 193(4):1317. PubMed ID: 25890537
[No Abstract] [Full Text] [Related]
3. Editorial comment to Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Maeda T
Int J Urol; 2014 Aug; 21(8):819-20. PubMed ID: 24942824
[No Abstract] [Full Text] [Related]
4. Reasons for prescription change of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Kim TN; Nam JK; Lee KS; Kim TH; Park SW; Shin DG; Park HJ; Lee W; Lee ZZ; Chung MK
Urology; 2014 Aug; 84(2):427-32. PubMed ID: 24972947
[TBL] [Abstract][Full Text] [Related]
5. Editorial comment to "Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin".
Fujimura T
Int J Urol; 2014 Jan; 21(1):113. PubMed ID: 23662925
[No Abstract] [Full Text] [Related]
6. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
[TBL] [Abstract][Full Text] [Related]
7. Editorial comment.
Zisman A
Urology; 2014 Feb; 83(2):421. PubMed ID: 24332125
[No Abstract] [Full Text] [Related]
8. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
Ito H; Sano F; Ogawa T; Yao M
Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
[TBL] [Abstract][Full Text] [Related]
9. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
[TBL] [Abstract][Full Text] [Related]
10. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report.
Curran MP
Drugs Aging; 2011 Oct; 28(10):843-5. PubMed ID: 21970311
[No Abstract] [Full Text] [Related]
11. The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
Lee YC; Juan YS; Liu CC; Bao BY; Wang CJ; Wu WJ; Huang CN; Huang SP
BJU Int; 2016 Aug; 118(2):313-9. PubMed ID: 26940040
[TBL] [Abstract][Full Text] [Related]
12. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?
Yamanishi T; Kaga K; Fuse M; Shibata C; Kamai T; Uchiyama T
Int J Urol; 2015 Dec; 22(12):1143-8. PubMed ID: 26310102
[TBL] [Abstract][Full Text] [Related]
13. Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.
Osman NI; Chapple CR; Cruz F; Desgrandchamps F; Llorente C; Montorsi F
Expert Opin Pharmacother; 2012 Oct; 13(14):2085-96. PubMed ID: 22924980
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy for non-neurogenic male lower urinary tract symptoms: 1 + 1 does not equal 2.
Lepor H
Eur Urol; 2013 Aug; 64(2):244-6; discussion 246-7. PubMed ID: 23473577
[No Abstract] [Full Text] [Related]
15. Monotherapy with α-blocker or phosphodiesterase 5 inhibitor for lower urinary tract symptoms?
Chapple CR
Eur Urol; 2012 May; 61(5):926-7. PubMed ID: 22397848
[No Abstract] [Full Text] [Related]
16. Experience with silodosin in «real life» (SiRE study).
Alcántara-Montero A
Actas Urol Esp; 2016 Oct; 40(8):534-5. PubMed ID: 27126124
[No Abstract] [Full Text] [Related]
17. [The role of alpha blockers in the treatment of lower urinary tract symptoms/benign prostatic hyperplasia: are all the same? Silodosin in "real life"].
Alcántara Montero A;
Semergen; 2016 Jul; 42 Suppl 2():1-9. PubMed ID: 27889014
[TBL] [Abstract][Full Text] [Related]
18. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
19. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
Sarma AV; Wei JT
N Engl J Med; 2012 Jul; 367(3):248-57. PubMed ID: 22808960
[No Abstract] [Full Text] [Related]
20. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
